Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL: Immunosuppression Withdrawal in Liver Transplant
NCT02533180Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2015
- Primary completion
- Feb 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in liver transplant, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Percent of Participants Who Achieve Operational Tolerance. Started Dec 2015; status: completed.
02
Conditions
liver transplant
Beyond the preview
Go deeper on NCT02533180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02533180.